|
Market Closed -
NSE India S.E.
15:05:10 28/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 1,920.00 INR | +0.35% |
|
+0.84% | +11.65% |
| 08-05 | CRISIL Keeps AAA Rating on Sun Pharmaceutical's Bank Facilities | MT |
| 07-31 | Sun Pharmaceutical Industries Limited, Q1 2027 Earnings Call, Jul 31, 2026 |
| Market Cap | 4,607B 48.2B 41.53B 38.94B 35.55B 66.97B 67.18B 462B 180B 2,325B 181B 177B 7,711B | P/E 2027 * |
35.4x | P/E 2028 * | 30x |
|---|---|---|---|---|---|
| Enterprise Value | 4,336B 45.37B 39.09B 36.65B 33.46B 63.03B 63.23B 435B 170B 2,189B 170B 167B 7,258B | EV / Sales 2027 * |
6.66x | EV / Sales 2028 * | 5.85x |
| Free-Float |
44.39% | Yield 2027 * |
0.89% | Yield 2028 * | 1.03% |
Last Transcript : Sun Pharmaceutical Industries Ltd.
| 1 day | +0.35% | ||
| 1 week | +0.84% | ||
| Current month | -3.54% | ||
| 1 month | -2.72% | ||
| 3 months | +4.10% | ||
| 6 months | +10.54% | ||
| Current year | +11.65% |
| 1 week | 1,892.6 |  | 1,931 |
| 1 month | 1,868.3 | | 2,046.9 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,548 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.35% | +0.84% | +19.98% | +73.55% | 48.07B | |
| -0.08% | -3.41% | +55.31% | +125.50% | 40.17B | |
| +0.15% | +7.52% | +20.56% | +89.26% | 12.42B | |
| +0.25% | -1.01% | -9.89% | +17.70% | 12.01B | |
| +0.19% | +0.19% | +30.98% | +150.00% | 9.38B | |
| +0.07% | +0.30% | +27.45% | +46.12% | 7.78B | |
| +0.04% | -0.99% | +52.61% | -10.90% | 7.24B | |
| +2.24% | +7.81% | +28.93% | +240.12% | 7.27B | |
| -0.53% | -6.81% | -35.67% | +17.62% | 5.33B | |
| +0.38% | -2.78% | +37.92% | +109.90% | 4.64B | |
| Average | +0.31% | +1.00% | +22.82% | +85.89% | 15.43B | |
| Weighted average by Cap. | +0.24% | +0.14% | +28.51% | +90.30% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 651B 6.81B 5.87B 5.5B 5.02B 9.46B 9.49B 65.29B 25.47B 329B 25.57B 25.02B 1,090B | 729B 7.63B 6.57B 6.16B 5.63B 10.6B 10.63B 73.12B 28.53B 368B 28.64B 28.02B 1,220B |
| Net income | 130B 1.36B 1.17B 1.1B 1B 1.88B 1.89B 13B 5.07B 65.45B 5.09B 4.98B 217B | 154B 1.61B 1.39B 1.3B 1.19B 2.23B 2.24B 15.41B 6.01B 77.56B 6.04B 5.9B 257B |
| Net Debt | -271B -2.83B -2.44B -2.29B -2.09B -3.93B -3.95B -27.15B -10.59B -137B -10.63B -10.4B -453B | -338B -3.54B -3.05B -2.86B -2.61B -4.92B -4.94B -33.94B -13.24B -171B -13.29B -13.01B -566B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/08/26 | ₹1,920.00 | +0.35% | 1,140,742 |
| 27/08/26 | ₹1,913.30 | +0.73% | 1,107,552 |
| 26/08/26 | ₹1,899.50 | -1.17% | 648,845 |
| 25/08/26 | ₹1,922.00 | +0.63% | 1,221,044 |
| 24/08/26 | ₹1,910.00 | +0.40% | 2,317,987 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
